Cardiff Oncology (Nasdaq: CRDF) closes $10.05M direct offering
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Cardiff Oncology entered into definitive agreements for a registered direct offering of 8,571,429 shares of common stock and accompanying warrants to purchase 8,571,429 shares, at $1.05 per share and warrant, pursuant to its shelf registration statement on Form S-3. Certain officers and directors are also purchasing additional shares and warrants at a higher per-share price.
The warrants have an exercise price of $1.31 per share for outside investors and $1.33 for insiders, become exercisable six months after issuance and after an authorized share increase, and expire five and one-half years after that date. Gross proceeds are approximately $10.05 million, to be used for working capital and general corporate purposes. H.C. Wainwright & Co. acts as exclusive placement agent, earning a 7.0% cash fee and a warrant for 465,157 shares at $1.3125 per share. Cardiff Oncology will seek stockholder approval to increase authorized common shares, committing to file a proxy within 45 days of closing and to hold repeated meetings until approval is obtained or the warrants are no longer outstanding.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 1.01, 8.01, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Shares sold: 8,571,429 shares of common stock
Offering price: $1.05 per share
Gross proceeds: approximately $10.05 million
+5 more
8 metrics
Shares sold
8,571,429 shares of common stock
Sold with accompanying warrants to institutional investors in the registered direct offering
Offering price
$1.05 per share
Purchase price per share of common stock and accompanying warrant in the primary offering
Gross proceeds
approximately $10.05 million
Total gross proceeds from the securities sold under the Purchase Agreement
Warrant exercise price
$1.31 per share
Exercise price of common warrants issued to non-insider investors
Insider warrant exercise price
$1.33 per share
Exercise price of common warrants issued to participating officers and directors
Placement agent warrant size
465,157 shares
Shares underlying the warrant issued to H.C. Wainwright, equal to 5.0% of shares sold
Placement agent warrant exercise price
$1.3125 per share
Exercise price of the warrant issued to the placement agent
Placement agent fee
7.0% of gross proceeds
Cash fee payable to H.C. Wainwright based on the offering’s gross proceeds
Key Terms
registered direct offering, shelf registration statement, placement agent, best efforts basis, +1 more
5 terms
registered direct offering financial
"at a purchase price of $1.05 per share and accompanying warrant in a registered direct offering"
A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.
shelf registration statement regulatory
"offered by the Company pursuant to its shelf registration statement on Form S-3"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
placement agent financial
"H.C. Wainwright & Co., LLC, as exclusive placement agent in connection with the Offering"
A placement agent is a professional or firm that helps organizations raise money from investors, such as individuals, institutions, or funds. They act like matchmakers, connecting those seeking investments with the right investors and guiding the process to ensure successful funding. For investors, they can provide access to exclusive opportunities and help navigate complex fundraising efforts.
best efforts basis financial
"agreed to act as placement agent on a reasonable “best efforts” basis in connection with the Offering"
PLK1 inhibition medical
"a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies"
PLK1 inhibition means blocking the activity of the enzyme Polo‑like kinase 1, a protein that helps cells divide. For investors, it signals a drug approach aimed at slowing or stopping fast‑growing tumors by disrupting the cell’s “division machinery,” but it also raises safety and trial‑success questions because the same process is important in healthy tissues; clinical results and side‑effect profiles drive the investment impact.
FAQ
What is the size and structure of Cardiff Oncology (CRDF)'s new offering?
Cardiff Oncology agreed to sell 8,571,429 shares of common stock and matching warrants to purchase 8,571,429 shares at $1.05 per share and warrant in a registered direct offering, plus additional shares and warrants to certain officers and directors at a higher price.
How much capital will Cardiff Oncology (CRDF) raise and how will it use the proceeds?
The transaction provides gross proceeds of approximately $10.05 million. Cardiff Oncology currently intends to use the net proceeds, after placement agent fees and expenses, for working capital and other general corporate purposes, supporting its ongoing operations and development programs.
What are the key terms of the warrants issued by Cardiff Oncology (CRDF)?
The common warrants have an exercise price of $1.31 per share ($1.33 for insiders), become exercisable six months after issuance and after an authorized share increase, and have a term of five and one-half years from their initial exercise date.
What compensation does H.C. Wainwright receive in the Cardiff Oncology (CRDF) financing?
H.C. Wainwright earns a cash fee equal to 7.0% of gross proceeds, a warrant to purchase 465,157 shares at $1.3125 per share, plus $35,000 for non-accountable expenses, $50,000 for legal and other expenses, and $15,950 for clearing fees.
Under which registration statement is the Cardiff Oncology (CRDF) offering being made?
The securities are offered under Cardiff Oncology’s Form S-3 shelf registration statement, File No. 333-285327, which was filed on February 27, 2025 and declared effective by the SEC on May 13, 2025, allowing this registered direct offering structure.